Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Celiprolol Hydrochloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 190Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Acer Receives Notice of Allowance of Key US Patent Application Covering EDSIVO
    Acer Receives Notice of Allowance of Key US Patent Application Covering EDSIVO

    26 Oct 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/10/26/2541822/0/en/Acer-Therapeutics-Receives-Notice-of-Allowance-of-Key-US-Patent-Application-Covering-EDSIVO-celiprolol.html

    GLOBENEWSWIRE
    26 Oct 2022
    Share Share
    Acer Therapeutics' EDSIVO Granted FDA BTD for Vascular Ehlers-Danlos Syndrome
    Acer Therapeutics' EDSIVO Granted FDA BTD for Vascular Ehlers-Danlos Syndrome

    04 Apr 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/04/04/2415756/0/en/Acer-Therapeutics-EDSIVO-celiprolol-Granted-FDA-Breakthrough-Therapy-Designation-for-Vascular-Ehlers-Danlos-Syndrome.html

    GLOBENEWSWIRE
    04 Apr 2022
    Share Share
    Acer Therapeutics Restructures Company, Eliminates 29 Employees
    Acer Therapeutics Restructures Company, Eliminates 29 Employees

    08 Jul 2019

    // Alex Keown BIOSPACE

    https://www.biospace.com/article/following-crl-acer-therapeutics-restructures-company-lays-off-29/

    Alex Keown BIOSPACE
    08 Jul 2019
    Share Share
    FDA kicks back Acer's rare disease drug, demands new test—shares in freefall
    FDA kicks back Acer's rare disease drug, demands new test—shares in freefall

    26 Jun 2019

    // Ben Adams FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/fda-kicks-back-acer-s-rare-disease-drug-demands-new-test-shares-freefall

    Ben Adams FIERCE BIOTECH
    26 Jun 2019
    Share Share
    FDA rejects Acer's rare disease drug, asks for new trial
    FDA rejects Acer's rare disease drug, asks for new trial

    24 Jun 2019

    // Natalie Grover ENDPTS

    https://endpts.com/fda-rejects-acers-rare-drug-asks-for-new-trial/

    Natalie Grover ENDPTS
    24 Jun 2019
    Share Share
    FDA accepts Acer, Kala NDAs before funding lapse
    FDA accepts Acer, Kala NDAs before funding lapse

    02 Jan 2019

    // Allison Johnson BIOCENTURY

    https://www.biocentury.com/bc-extra/company-news/2018-12-26/fda-accepts-acer-kala-ndas-funding-lapse

    Allison Johnson BIOCENTURY
    02 Jan 2019
    Share Share